Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

d a Phase 3 study of intravenous (i.v.) peramivir for seasonal influenza in the outpatient setting. Patient enrollment is underway in Japan and other countries in eastern Asia. The study will enroll approximately 1,000 patients. Shionogi initiated this Phase 3 study based on positive clinical results from a Phase 2 study that investigated the efficacy and safety of a single administration of i.v. peramivir 300 mg or 600 mg for the treatment of seasonal influenza in the outpatient setting. The Phase 2 study results were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th Annual Meeting in a poster titled "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients." In the Phase 2 study, the primary efficacy endpoint, time to alleviation of symptoms (TTAS), was significantly shorter in both peramivir arms compared to placebo.

  • BioCryst will present results from the previously announced exploratory Phase 2 study of i.v. peramivir in patients hospitalized for acute serious or potentially life-threatening influenza in an oral presentation at the XI International Symposium on Respiratory Viral Infections, being held in Bangkok, Thailand, February 19-22, 2009.

Forodesine HCl Program

  • BioCryst continues to enroll patients in the Phase 2 pivotal study of Forodesine HCl in patients with cutaneous T-cell lymphoma (CTCL), and has enrolled more than half of the targeted patients. The study will enroll approximately 130 patients and the Company expects to report top-line data in the first half of 2010.

  • BioCryst announced interim data from the ongoing Forodesine HCl Phase 2 program in patients with chronic lymphocytic leukemia (CLL) and data from a healthy subject
    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... LLC has been awarded a Phase I Small Business ... Institute on Aging. The project is focused on identifying ... (fat) that are regulated by a calorie restricted ... at LifeGen, the technology developed under the NIH ...
... In honor of National Chemistry Week (NCW), ... in San Diego, California, has joined with Herbert Hoover ... of chemistry in our everyday lives. National ... American Chemical Society (ACS) to unite local ACS ...
... Md., Oct. 21 United Therapeutics Corporation (Nasdaq: ... its third quarter 2010 financial results before market open ... will host a half-hour teleconference on Thursday, October 28, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. ...
Cached Biology Technology:LifeGen Technologies Awarded NIH Grant to Identify Biomarkers of a Calorie Restricted Diet in Adipose Tissue 2MicroConstants Celebrates National Chemistry Week by Teaching San Diego High School Students About the Drug Development Process 2
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday ... biometrics industry as Acuity Market Intelligence reports that ... finally be open. Acuity forecasts that intensifying demand ... that incorporate biometrics will drive a global market ... biometric devices by 2020.   According ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... suggest that policy makers examine greenhouse gas (GHG) ... sources must be rapidly replaced by windmills, solar ... recommendations could be used to help policy makers ... will optimize greenhouse gas emission reductions., "The energy ...
... scientists from Princeton University and The Cancer Institute of New ... the secret lives of cancer cells that go dormant and ... produce new cancer therapies to stem changes that render cancer ... know: What role is this self-cannibalization playing in the middle ...
... aerospace and ocean engineering at Virginia Tech, is the latest ... a National Science Foundation (NSF) Faculty Early Career Development (CAREER) ... 70 Virginia Tech CAREER award winners, of which some 60 ... award was created in 1994. He will receive some $400,000 ...
Cached Biology News:Queen's researchers propose rethinking renewable energy strategy 2Research team targets self-cannibalizing cancer cells 2Research team targets self-cannibalizing cancer cells 3Research team targets self-cannibalizing cancer cells 4Research team targets self-cannibalizing cancer cells 5Engineer studies tensional integrity of biological structures 2Engineer studies tensional integrity of biological structures 3
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
...
Mouse Amphiregulin MAb (Clone 206220)...
Biology Products: